Lesson plan
ExPEC10V
ExPEC10V, also known as VAC-52416 or JNJ-69968054, is a vaccine against Escherichia coli infection. It is an Escherichia coli polysaccharide conjugate vaccine. The vaccine is administered by intramuscular injection. It is being developed by Janssen Pharmaceuticals. As of April 2023, ExPEC10V is in phase 3 clinical trials. It is under development towards approval in the United States, Europe, and Japan. The vaccine is a 10-valent form of the earlier ExPEC4V.
Article summary
ExPEC10V, also known as VAC-52416 or JNJ-69968054, is a vaccine against Escherichia coli infection. It is an Escherichia coli polysaccharide conjugate vaccine. The vaccine is administered by intramuscular injection. It is being developed by Janssen Pharmaceuticals. As of April 2023, ExPEC10V is in phase 3 clinical trials. It is under development towards approval in the United States, Europe, and Japan. The vaccine is a 10-valent form of the earlier ExPEC4V.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.